Clinical trial • Phase I • Oncology
FS222 for Advanced malignancies | Advanced cancer
Phase I trial of FS222 for Advanced malignancies | Advanced cancer. None/Not specified-controlled. 38 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced malignancies | Advanced cancer
- Trial Stage
- Phase I
- Drug Modality
- Other antibody
Key dates
- Initial CTIS Submission Date
- 29-05-2024
- First CTIS Authorization Date
- 17-06-2024
Trial design
None/Not specified-controlled Phase I trial across 25 sites in Spain, Poland, Romania and others.
- Comparator
- None/Not specified
- Target Sample Size
- 38
Recruitment
- Planned Sample Size
- 38
- Recruitment Window Months
- 78
Geography
- Total Number Of Sites
- 25
- Total Number Of Participants
- 323
Spain
- Earliest CTIS Part Ii Submission Date
- 12-06-2024
- Latest Decision Or Authorization Date
- 02-03-2026
- Processing Time Days
- 628
- Number Of Sites
- 12
- Number Of Participants
- 234
Sites
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology Department
- Contact Person Name
- Guillermo Antonio de Velasco Oria de Rueda
- Contact Person Email
- gdevelasco.gdv@gmail.com
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Medical Oncology Department
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Medical Oncology Department
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology Department
- Contact Person Name
- Elena Garralda Cabanas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Medical Oncology Department
- Contact Person Name
- Guzman Alonso Casal
- Contact Person Email
- galonso@nextoncology.eu
- Site Name
- Complejo Hospitalario Universitario Insular Materno Infantil
- Department Name
- Medical Oncology Department
- Contact Person Name
- Delvys Rodriguez Abreu
- Contact Person Email
- drodabr@gobiernodecanarias.org
- Site Name
- Hospital Universitario Virgen De La Macarena
- Department Name
- Medical Oncology Department
- Contact Person Name
- Teresa Garcia Manrique
- Contact Person Email
- tgarciamanrique.onco@gmail.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Medical Oncology Department
- Contact Person Name
- Ignacio Melero Bermejo
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Universitario Puerta De Hierro De Majadahonda
- Department Name
- Medical Oncology Department
- Contact Person Name
- Mariano Provencio Pulla
- Contact Person Email
- mprovencio.ensayosclinicos@gmail.com
- Site Name
- Institut Catala D'oncologia
- Department Name
- Medical Oncology Department
- Contact Person Name
- Maria Ochoa de Olza Amat
- Contact Person Email
- maochoa@iconcologia.net
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Medical Oncology Department
- Contact Person Name
- Ivan Manuel Victoria Ruiz
- Contact Person Email
- ivictori@recerca.clinic.cat
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Medical Oncology Department
- Contact Person Name
- Andres Cervantes Ruiperez
- Contact Person Email
- andres.cervantes@uv.es
Poland
- Earliest CTIS Part Ii Submission Date
- 04-03-2025
- Latest Decision Or Authorization Date
- 06-04-2025
- Processing Time Days
- 359
- Number Of Sites
- 4
- Number Of Participants
- 12
Sites
- Site Name
- Pratia S.A.
- Contact Person Name
- Anna Drosik-Kwaśniewska
- Contact Person Email
- adrosik-kwasniewska@pratia.pl
- Site Name
- Biokinetica S.A.
- Contact Person Name
- Rafał Stec
- Contact Person Email
- drrafals@wp.pl
- Site Name
- Pratia Hematologia Sp. z o.o.
- Contact Person Name
- Agata Kachel-Flis
- Contact Person Email
- agata.kachel-flis@pratia.com
- Site Name
- Pratia S.A.
- Contact Person Name
- Marek Kotlarski
- Contact Person Email
- marek.kotlarski@pratia.com
Romania
- Earliest CTIS Part Ii Submission Date
- 12-06-2024
- Latest Decision Or Authorization Date
- 02-03-2026
- Processing Time Days
- 628
- Number Of Sites
- 2
- Number Of Participants
- 35
Sites
- Site Name
- Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
- Department Name
- Phase 1 Unit, Radiotherapy
- Contact Person Name
- Tudor Eliade Ciuleanu
- Contact Person Email
- tudor.ciuleanu.ext@arensia-em.com
- Site Name
- Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
- Department Name
- Phase 1 Unit, Medical Oncology II, Radiotherapy I
- Contact Person Name
- Nicoleta Laurentia Gales
- Contact Person Email
- laurentia.gales.ext@arensia-em.com
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-03-2025
- Latest Decision Or Authorization Date
- 27-02-2026
- Processing Time Days
- 337
- Number Of Sites
- 3
- Number Of Participants
- 12
Sites
- Site Name
- Leids Universitair Medisch Centrum (LUMC)
- Department Name
- Medische Oncologie
- Contact Person Name
- Frank Speetjens
- Contact Person Email
- f.m.speetjens@lumc.nl
- Site Name
- Radboud universitair medisch centrum Stichting
- Department Name
- Medische Oncologie
- Contact Person Name
- Carla van Herpen
- Contact Person Email
- carla.vanherpen@radboudumc.nl
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medische Oncologie
- Contact Person Name
- Tim Schutte
- Contact Person Email
- fase1@nki.nl
Germany
- Earliest CTIS Part Ii Submission Date
- 14-03-2025
- Latest Decision Or Authorization Date
- 26-02-2026
- Processing Time Days
- 349
- Number Of Sites
- 4
- Number Of Participants
- 30
Sites
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- Klinik für Dermatologie, Venerologie und Allergologie
- Contact Person Name
- Dirk Schadendorf
- Contact Person Email
- Hautklinik.Studienzentrum@heh.uk-essen.de
- Site Name
- SLK-Kliniken Heilbronn GmbH
- Department Name
- Klinikum am Gesundbrunnen
- Contact Person Name
- Uwe Martens
- Contact Person Email
- uwe.martens@slk-kliniken.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Early Clinical Trial Unit (ECTU)
- Contact Person Name
- Sebastian Ochsenreither
- Contact Person Email
- sebastian.ochsenreither@charite.de
- Site Name
- Technische Universitaet Dresden
- Department Name
- Medizinische Fakultät Carl Gustav Carus Nationales Centrum für Tumorerkrankungen Dresden (NCT/UCC)
- Contact Person Name
- Martin Wermke
- Contact Person Email
- Martin.Wermke@uniklinikum-dresden.de
Sponsor
Primary sponsor
- Full Name
- Invox Pharma Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- FS222
- Modality
- Other antibody
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)